Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports

Introduction As asthma medications are frequently prescribed for children, knowledge of the safety of these drugs in the paediatric population is important. Although spontaneous reports cannot be used to prove causality of adverse events, they are important in the detection of safety signals. Object...

Full description

Saved in:

Bibliographic Details
Published in:	Drug safety 2020-01, Vol.43 (1), p.7-16
Main Authors:	Baan, Esmé J., de Smet, Veronique A., Hoeve, Christina E., Pacurariu, Alexandra C., Sturkenboom, Miriam C. J. M., de Jongste, Johan C., Janssens, Hettie M., Verhamme, Katia M. C.
Format:	Article
Language:	eng
Subjects:	Age Asthma Budesonide Children Drug Safety and Pharmacovigilance Drugs Identification methods Immunoglobulin E Medicine Medicine & Public Health Monoclonal antibodies Original Original Research Article Pharmacology/Toxicology Sex Side effects Theophylline Therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction As asthma medications are frequently prescribed for children, knowledge of the safety of these drugs in the paediatric population is important. Although spontaneous reports cannot be used to prove causality of adverse events, they are important in the detection of safety signals. Objective Our objective was to provide an overview of adverse drug events associated with asthma medications in children from a spontaneous reports database and to identify new signals. Methods Spontaneous reports concerning asthma drugs were obtained from EudraVigilance, the European Medicine Agency’s database for suspected adverse drug reactions. For each drug–event combination, we calculated the proportional reporting ratio (PRR) in the study period 2011–2017. Signals in children (aged 0–17 years) were compared with signals in the whole population. Analyses were repeated for different age categories, by sex and by therapeutic area. Results In total, 372,345 reports in children resulted in 385 different signals concerning asthma therapy. The largest group consisted of psychiatric events (65 signals). Only 30 signals were new, with seven, including herpes viral infections, associated with omalizumab. Stratification by age, sex and therapeutic area provided additional new signals, such as hypertrichoses with budesonide and encephalopathies with theophylline. Of all signals in children, 60 (16%) did not appear in the whole population. Conclusions The majority of signals regarding asthma therapy in children were already known, but we also identified new signals. We showed that signals can be masked if age stratification is not conducted. Further exploration is needed to investigate the risk and causality of the newly found signals.
ISSN:	0114-5916 1179-1942